Celltrion executive Kim Hyoung-ki said that the company expects to sell Remsima （biosiimiliar Drug of Remicade) at a 30 percent discount to Remicade, aiming to win a significant chunk of the $6.1 billion sales that the drug racked up for Johnson & Johnson in 2012.好大口气。展开全文 原微博
